Investing in Altria: A Reliable Option for Uncertain Markets

Dec.02.2022
Investing in Altria: A Reliable Option for Uncertain Markets
Investors seeking stability can look to tobacco giant Altria Group for reliable dividend income amid market volatility.

The volatile markets we witnessed in 2022 remind us of the importance of stability for investors. Retirees or others seeking dividends may want to consider investing in tobacco giant Altria Group (MO 0.92%) to stabilize their portfolio and put some money in their pockets.


This stock only dropped 4% in 2022 and paid a generous dividend yield of 8.5% to investors. As Wall Street enters 2023 with some uncertainty, the reliability of such a high yield may be more attractive to investors.


Altria may not be a suitable stock for everyone, but this is why those who hold it can sleep well at night knowing their investment is generating reliable dividend income.


During this period, the stock price fell by 32% as a result of Altria's disastrous failure after acquiring a stake in the e-cigarette company Juul for approximately $13 billion in 2018 and subsequently seeing its value evaporate due to regulatory scrutiny.


However, that was then; now, the stock of Altria reflects that mistake, with a price-to-earnings ratio (P/E) just above 9, significantly lower than the median P/E of the stock over the past decade (P/E of 17). This doesn't mean that the stock price can't still go down, but the discount on Altria's long-term fundamentals may provide a safety margin - bad news has already been factored in.


This may be one of the reasons why Altria is holding steady this year. I suspect that if the stock were traded at a higher valuation - for example, above its ten-year average - it would fall further in this bear market.


An 8.5% reliable dividend yield.


Since the 1960s, Americans have known that cigarettes are harmful to your health, but Altria has continued to make more money. In 2012, Altria shipped 136 billion units of tobacco products, while in 2021 they only shipped 95 billion units. However, the operating profit from tobacco products grew from $6.2 billion to $10.4 billion. This highlights Altria's pricing power due to the addictive nature of their products.


For years, these rising prices have supported Altria's financial health, making it a dividend king that has seen 52 consecutive years of increases.


YCharts provides data on the cash dividend payout ratio for MO.


Investors may be worried about the 81% dividend payout ratio, but they should not be overly concerned. Altria's business does not require a lot of capital; it can distribute the majority of profits to shareholders and still operate successfully. While the business may not be exciting, it has proven to be very effective in generating cash for investors.


Resting in an emergency situation.


It appears reasonable to assume that Altria's rinse-and-repeat model of raising prices will not be effective forever, and the management seems to understand this, as evidenced by their investments in Juul and Cronos Group in an attempt to diversify their business. Altria is still working towards creating a future beyond cigarettes, and investors should monitor their progress over the long term. However, if necessary, the company has significant leverage to generate additional cash.


Altria owns a 10% stake in global brewer AB InBev, which, based on today's stock price, is valued at approximately $11 billion. If Altria were to sell this stake, the resulting cash would be roughly one-eighth of Altria's market value, providing ample funds for stock buybacks or debt repayment. Altria could almost entirely pay off the debt it incurred when investing in Juul.


2FIRSTS will continue to track and report on this issue, with updates available on the "2FIRSTSAPP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15